Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Sep 2025 value amounting to $1.1 billion.

  • Madrigal Pharmaceuticals' Cash & Current Investments rose 11.13% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 1.96%. This contributed to the annual value of $926.3 million for FY2024, which is 46.07% up from last year.
  • Madrigal Pharmaceuticals' Cash & Current Investments amounted to $1.1 billion in Q3 2025, which was up 39.24% from $797.0 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Cash & Current Investments peaked at $1.1 billion during Q3 2025, and registered a low of $153.2 million during Q3 2022.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Cash & Current Investments value was $843.1 million (recorded in 2025), while the average stood at $753.3 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 48.79% in 2022, then surged by 329.79% in 2024.
  • Quarterly analysis of 5 years shows Madrigal Pharmaceuticals' Cash & Current Investments stood at $270.3 million in 2021, then skyrocketed by 32.71% to $358.8 million in 2022, then skyrocketed by 76.75% to $634.1 million in 2023, then skyrocketed by 46.07% to $926.3 million in 2024, then increased by 11.13% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $797.0 million for Q2 2025, and $843.1 million during Q1 2025.